GLP-1 Drugs, formally known as Glucagon-Like Peptide-1 receptor agonists, represent one of the most significant medical advances of the past two decades in the treatment of type 2 diabetes and obesity. Originally developed to control blood sugar, these drugs have gained global attention for their powerful weight-loss effects and potential benefits for heart, kidney, and metabolic health.
With rising rates of diabetes and obesity worldwide, including in India. GLP-1 drugs are increasingly viewed as game-changers in chronic disease management.
What is GLP-1?
GLP-1 is a naturally occurring hormone produced in the gut after eating. It plays a crucial role in regulating metabolism by:
- Stimulating insulin release when blood sugar rises.
- Suppressing glucagon ( a hormone that raises blood sugar)
- Slowing gastric emptying (food leaves the stomach more slowly)
- Acting on the brain to reduce appetite and increase satiety.
In people with type-2 diabetes or obesity, the GLP-1 response is often impaired, leading to poor blood sugar control and overeating.
How GLP-1 Drugs Work
They act through multiple mechanisms:
1 Blood Sugar Control– They increase insulin secretion only when glucose levels are high, reducing the risk of hypoglycemia compared to older diabetes drugs.
2 Appetite Suppression– By acting on appetite centers in the brain, GLP-1 drugs significantly reduce hunger and food cravings.
3 Slower Digestion– They delay gastric emptying, helping people feel full longer after meals.
4 Weight Loss– Reduced calorie intake combined with improved insulin sensitivity leads to sustain weight loss.
Common GLP-1 drugs are Semaglutide, Liraglutide, Dulaglutide, Exenatide, and Tirzepatide.
GLP-1 Drugs and Weight Loss
Clinical trials on some GLP-1 drugs have shown remarkable results
- Semaglutide- 12-15% average body weight reduction.
- Tirzepatide- up to 20-25% weight loss in some patients.
- Weight loss is typically gradual and sustained with continued use.
This has led to the approval of certain GLP-1 drugs specifically for obesity, even in people without diabetes, in the USA.
Cardiovascular and other Health Benefits
Beyond diabetes and weight loss, GLP-1 drugs have demonstrated:
- Reduced risk of heart attack and stroke.
- Improved blood pressure.
- Potential kidney protection in diabetics.
- Reduced liver fat in non-alcoholic fatty liver disease.
- Possible benefits in sleep apnea and joint health due to weight reduction
Common side effects are– Nausea, Vomiting, Diarrhea or Constipation, and loss of appetite. These usually occur early and improve over time.
Serious but rare risks– These are Pancreatitis, Gallbladder disease, and possible risk of thyroid C-cell tumours (seen in animals, not proven in humans)
Who Should Avoid GLP-1 Drugs?
- Patients with a history of medullary thyroid cancer.
- People with multiple endocrine neoplasia syndrome
- Pregnant or breastfeeding women.
GLP-1 Drugs in India
In India, GLP-1 drugs are increasingly prescribed for diabetes, but their use for obesity is limited by
- High cost (often Rs 10,000 to 25,000 per month)
- Limited insurance coverage
- Need for long term or lifelong treatment.
As obesity and diabetes continue to rise, demand for more affordable GLP-1 formulations and generics is growing.
Ethical and Social Debate
The popularity of GLP-1 drugs has sparked debate:
- Should these drugs be used for cosmetic weight loss?
- Are they diverting supply from diabetic patients?
- Will long-term dependence on medication reduce emphasis on lifestyle changes?
Most experts agree that GLP-1 drugs should be used as medical therapy, not quick fix.
In the end, GLP-1 drugs represent a major leap forward in managing diabetes and obesity, offering benefits far beyond blood sugar control. While not without risks or limitations, they are going to reshape modern metabolic medicines and are going to open new possibilities for tackling some of the world’s most pressing health concerns like diabetes and obesity.
These drugs are to be used under strict medical supervision, as they could significantly improve quality of life and reduce burden of chronic diseases.
Anil Malik
Mumbai, India
7th January 2026
Minoo Malik
Very informative Anil bhaiya!